Member Info for gtc1507

OptiPhageTM, a phage display based version of the same DNA library. OptiPhageTM uses the same DNA sequences as OptiMAL® but packages them into a more commonly used Phage display format. Only smaller antibody fragments can be screened in this way, compared to whole antibodies via OptiMAL®, but it can be run at a lower price point for the customer. The Directors believe that the provision of OptiPhageTM provides the Company with an ability to protect the premium pricing of the OptiMAL® programme whilst meeting budgetary constraints of its customers. It may also be the platform of choice for those wanting antibody fragments as their end product; and

Great news they’ve been able to commercialise this new technology platform with great potential for royalties on antibodies developed and sold.

You’ve still not given any more on these rumours…

If you’re hearing good news you should give some detail…

What rumours Chris….

CEO has posted on LinkedIn that they’ve converted many antibodies for Vet Med purposes. a good indication they’re getting traction in this new market then as they weren’t previously operating in this space.

https://www.linkedin.com/posts/adrian-kinkaid-4067395_vetmed-antibodies-challengeus-activity-7183489110097993728-lgqS?utm_source=share&utm_medium=member_ios

Be great if we can close over this level

Massive trade earlier today! hopefully we get some news soon

Https://www.linkedin.com/posts/fusion-antibodies-plc_nih-nci-optimal-activity-7179413612925513728-KP5L?utm_source=share&utm_medium=member_ios

Looks like a pretty good presentation group to showcase their technology!

That’s not accurate about large shareholders selling on 11/3.

The two large investors % adjusted as a result of the placing. One of those if you look at it has invested more and the other has just been diluted down without selling

Amati is an acquisition. Their % is only decreasing very slightly despite a significant increase in shares in circulation.

as at end of FY22 they held 2,341,463 and now they’re holding 4,761,463.

Good to see existing IIs buying in

Notice of AGM contains the following statement:

Directors estimate company currently has a cash runway to October 2024.

Sign that their conservative cost control still seems to be working and journey to cash neutrality is going well.

Have you bought back in Chris?

Https://wp-allenby-2020.s3.eu-west-2.amazonaws.com/media/2024/02/20240215-Fusion-Antibodies-plc-FAB.L-Allenby-Capital-Update.pdf?c4036=on

Company has just announced 4 new staff appointments and that it is accepting speculative applications to meet increasing demand for its new services on LinkedIn

I think something not taken from this RNS but possible is the impact of the statement about the existing contract bringing in revenues higher than the previously agreed amount.

Allenby Capital briefing note last year said they had only earned $300k from this contract in 2022/23 as it had been moving slower than anticipated.

RNS suggests they’ve now received more than the full contract amount of $1.83m for the existing contract.

This should be a good boost for 23/24 and if already included as part of their forecast expected revenue then one assumes they're still on target and both CEO and CFO said if they hit their H2 targets they won't need to raise cash.

If it's greater amount than forecast then potentially a good boost on the runway.

On the longer term they’re also entitled to royalty and milestones from this contract which bodes well for the future

"One of its customers, OncoResponse, however, has now been disclosed, with a very positive commendation provided in connection with the manufacturability of the antibody. Although not confirmed, we suspect that this comment relates to OncoResponse’s antiLILRB2/ILT4 antibody. This appears to be in late preclinical studies as an approach to immune regulation of cancer"

From Allenby briefing note on 19th May 23 - one of their RAMP Customers as well so shows diversity of their platforms.

Allenby indicated the Antibody FAB working on with this client is likely OR502, anti-LILRB2 Antibody.

According to Oncoresponse, the client, this antibody entered Phase 1/2 trials in November 23 - great development for FAB who if have said they are entitled to milestones and royalties from this client collaboration.

https://www.prnewswire.com/news-releases/oncoresponse-announces-initiation-of-phase-12-clinical-trial-of-or502-anti-lilrb2-antibody-in-subjects-with-advanced-cancer-302000171.html

I think the key for this years revenue is the fact that the original contract has now been completed, at a value above the original amount. This was one of the contracts that has been delayed and so these will be revenues that are recognised in this financial year. Hopefully good news for on target to cash neutrality!

Expect a sea of blue trades today! 200 day moving average is only 8 - could easily see that broken and golden cross bounce!!